miranda riley's lawyer, mike pearson, responded to that in a letter he sent congress.ing there is absolutely no truth to the statement that my client was not willing to provide relevant testimony to the faa. for the tci grads left stranded, attorney mike pearson is convinced there's a discrimination complaint. >> it can be anywhere from 2,000 to 3,000 potentially plaintiffs. >> with thousands of air traffic controllers facing retirement, the transparent hiring of a workforce so important to safety and yes, national security should be the concern of all americans. these graduates remain committed to aviation. and still one day hope to fulfill their dream of working in the towers. >> there's 3,000 of us who are more than willing to do the work. so if anyone wants to reach out to us. please do. we're readily, we're passionate. we want to work. >> the bipartisan members of congress that introduced the air traffic controllers hiring act stated that the faa has and this is a quote, clearly jeopardized all travel safety. those are serious accusations, charges that should be o

on monday, ceo mike pearson denied the business model is dependent on price hikes. they have put out a note laying the blame for skyrocketing drug prices directly on valeant. it says it's a malignant tumor on the u. s. health care system that needs to be removed before it effects all other healthy company. >> we're off by 1.4%. the etf suffering the biggest one day drop in four years yesterday. it's down 20% over the last 7 trading sessions. trading volume is at 11.7 million shares a day. that's 11 times the usual average. you just have to wonder what's going to stop this bleeding in bio tech stocks. we have third quarter earning season coming up. that could be a catalyst also. maybe better study results or what's been driving the sector all along this year, m&a. >> i don't think it's a popular season to be hiking your drug prices right now. so valeant, they increase these heart drugs by 212%. 525% for nitropress and we have been hearing this fire storm of criticism levied at these pharmaceutical companies. they bore the brunt of a lot of criticism and anger really.

i talked with valeant ceo mike pearson today who said they're not afraid to go after the big deal they're still looking at those opportunistically and they would consider another big deal if it makes sense for shareholders. they're looking there. but valeant definitely not slowing down. pearson telling me that all the volatility we're seeing in the market right now makes him more opportunist i can about doing deals. >> meg, thank you. meg tirrell. valeant by the way is up 93% over the past 12 months. >> listen, if this market volatility continues, whatever the reason, these deals are done. you may see some of these big blockbuster ones but the little ones are done. the things that have powered the xbi so much higher over the last 18 months, it's done. >> why couldn't a big name like valeant or celgene or a biogen or gilead continue -- >> yeah. i think we have a structural thing going on in biotech and there are some very deep pockets chasing. i think the smaller deals are the ones that probably can still go. you look at valeant this is a name that although there's probably as a lot of the